Jaime Uribarri, MD Email Jaime Uribarri
- PROFESSOR | Medicine, Nephrology
- Hospital Affiliation
- The Mount Sinai Hospital
- Department of Medicine-Renal Medicine 212-241-4060 212-241-4060
Book an Appointment - Jaime Uribarri, MD
American Board of Internal Medicine
MD, University of Chile Medical School
Residency, Internal Medicine
The Brooklyn Hospital
Residency, Internal Medicine
Brooklyn Hospital-Caledonian Hosp.
Downstate Medical Center
Advanced glycoxidation end products as cardiovascular risk factors in renal failure
Serum levels of advanced glycoxidation end products (AGE) are elevated in diabetes, renal failure and advanced age and these compounds are thought to mediate, at least in part, many of the vascular complications associated with these conditions. AGEs are a heterogeneous group of compounds formed from the non-enzymatic reaction of reducing sugars with the free amino groups of proteins. It had been assumed that circulating AGE originate exclusively from endogenous sources but now it has become clear that foods contain a variable amount of pre-formed AGE and AGE-precursors that contribute to the body AGE pool.We have recently demonstrated that serum AGE levels correlate with dietary AGE content in ESRD patients on dialysis. When a subgroup of these patients was randomized to follow a diet low in AGE content for 4 weeks, we observed 30% of decrease of serum AGE levels and parallel changes in CRP levels. These studies suggest that dietary AGEs play an important role in determining the body AGE pool and that dietary AGE modulation is a feasible, safe and effective way to decrease body AGE pool. Our working hypothesis is that AGEs represent independent risk factors for cardiovascular disease in renal failure patients. Our next research phase will try to demonstrate in a larger number of patients that low AGE diet can reduce serum AGE levels and at the same time improve the direct markers of vascular structure and function: brachial artery dilatation in response to hyperemia and arterial stiffness.
Other areas of research interest include:
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Uribarri during 2018 and/or 2019. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.